Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8351679rdf:typepubmed:Citationlld:pubmed
pubmed-article:8351679lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:8351679lifeskim:mentionsumls-concept:C0015056lld:lifeskim
pubmed-article:8351679lifeskim:mentionsumls-concept:C0851347lld:lifeskim
pubmed-article:8351679lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8351679lifeskim:mentionsumls-concept:C1113707lld:lifeskim
pubmed-article:8351679pubmed:issue2lld:pubmed
pubmed-article:8351679pubmed:dateCreated1993-9-14lld:pubmed
pubmed-article:8351679pubmed:abstractTextThe influence of dimeticone (Gel de Polysilane Midy) on the pharmacokinetics and pharmacodynamics of oral ethyl biscoumacetate was studied in 6 healthy volunteers in a randomised single dose, two-way cross-over study. Each volunteer received at one week interval a single dose (300 mg) of ethyl biscoumacetate, either alone or with dimeticone. Ethyl biscoumacetate levels were measured in plasma for 24 hours. Pharmacodynamic parameters were measured for 96 hours. Ethyl biscoumacetate peak concentration was significantly higher when administered with dimeticone (40.3 +/- 25.3 mg/l vs 31.0 +/- 25.7 mg/l; p = 0.031), without significant change in the area under curve. Other pharmacokinetic and pharmacodynamic parameters did not differ significantly. The slight increase of the ethyl biscoumacetate bioavailability with dimeticone in repeated dosing might have pharmacodynamic consequence; a clinical trial should address this question.lld:pubmed
pubmed-article:8351679pubmed:languagefrelld:pubmed
pubmed-article:8351679pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8351679pubmed:citationSubsetIMlld:pubmed
pubmed-article:8351679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8351679pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8351679pubmed:statusMEDLINElld:pubmed
pubmed-article:8351679pubmed:issn0040-5957lld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:SHOYYlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:OliveGGlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:de LautureDDlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:StrauchGGlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:ChanteclairGGlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:LetraitMMlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:PelloJ YJYlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:PinquierJ LJLlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:CraigT TTTlld:pubmed
pubmed-article:8351679pubmed:authorpubmed-author:PaltiatM HMHlld:pubmed
pubmed-article:8351679pubmed:issnTypePrintlld:pubmed
pubmed-article:8351679pubmed:volume48lld:pubmed
pubmed-article:8351679pubmed:ownerNLMlld:pubmed
pubmed-article:8351679pubmed:authorsCompleteYlld:pubmed
pubmed-article:8351679pubmed:pagination119-23lld:pubmed
pubmed-article:8351679pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8351679pubmed:meshHeadingpubmed-meshheading:8351679-...lld:pubmed
pubmed-article:8351679pubmed:meshHeadingpubmed-meshheading:8351679-...lld:pubmed
pubmed-article:8351679pubmed:meshHeadingpubmed-meshheading:8351679-...lld:pubmed
pubmed-article:8351679pubmed:meshHeadingpubmed-meshheading:8351679-...lld:pubmed
pubmed-article:8351679pubmed:meshHeadingpubmed-meshheading:8351679-...lld:pubmed
pubmed-article:8351679pubmed:articleTitle[Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate].lld:pubmed
pubmed-article:8351679pubmed:affiliationInstitut de Recherche Thérapeutique (IRT-Eclimed), Hôpital Cochin, Paris.lld:pubmed
pubmed-article:8351679pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8351679pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8351679pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:8351679pubmed:publicationTypeRandomized Controlled Triallld:pubmed